Waters (NYSE:WAT)‘s stock had its “hold” rating restated by investment analysts at Barclays in a report issued on Monday. They currently have a $202.00 price objective on the medical instruments supplier’s stock. Barclays’ target price would indicate a potential downside of 3.33% from the stock’s current price.

Other analysts also recently issued reports about the company. Goldman Sachs Group assumed coverage on Waters in a research report on Tuesday, September 26th. They set a “hold” rating and a $180.00 price objective for the company. Zacks Investment Research raised Waters from a “hold” rating to a “buy” rating and set a $211.00 price objective for the company in a research report on Monday, October 23rd. Citigroup restated a “neutral” rating and set a $180.00 target price on shares of Waters in a report on Wednesday, October 25th. Morgan Stanley restated an “underweight” rating and set a $192.00 target price (up from $183.00) on shares of Waters in a report on Friday, October 6th. Finally, BTIG Research initiated coverage on Waters in a report on Friday, January 5th. They set a “buy” rating and a $230.00 target price for the company. Eleven research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Hold” and an average target price of $197.33.

Shares of Waters (NYSE:WAT) opened at $208.96 on Monday. The company has a current ratio of 6.16, a quick ratio of 5.71 and a debt-to-equity ratio of 0.66. The stock has a market capitalization of $16,620.00, a PE ratio of 30.82, a P/E/G ratio of 2.71 and a beta of 0.82. Waters has a 52-week low of $136.14 and a 52-week high of $210.08.

Waters (NYSE:WAT) last issued its quarterly earnings data on Tuesday, October 24th. The medical instruments supplier reported $1.77 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.74 by $0.03. The firm had revenue of $565.58 million during the quarter, compared to the consensus estimate of $555.25 million. Waters had a return on equity of 23.61% and a net margin of 24.34%. The company’s quarterly revenue was up 7.4% on a year-over-year basis. During the same period last year, the company earned $1.57 EPS. analysts predict that Waters will post 7.42 earnings per share for the current fiscal year.

In other news, Director Thomas P. Salice sold 3,500 shares of Waters stock in a transaction dated Monday, November 20th. The stock was sold at an average price of $200.03, for a total value of $700,105.00. Following the completion of the transaction, the director now owns 20,349 shares in the company, valued at approximately $4,070,410.47. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Joann A. Reed sold 1,386 shares of Waters stock in a transaction dated Tuesday, January 2nd. The shares were sold at an average price of $194.07, for a total value of $268,981.02. The disclosure for this sale can be found here. Insiders have sold a total of 93,159 shares of company stock valued at $18,412,172 over the last 90 days. 5.07% of the stock is currently owned by company insiders.

Several institutional investors and hedge funds have recently made changes to their positions in the company. Progressive Investment Management Corp boosted its stake in shares of Waters by 1.3% in the 4th quarter. Progressive Investment Management Corp now owns 22,606 shares of the medical instruments supplier’s stock valued at $4,367,000 after buying an additional 285 shares during the period. Copper Rock Capital Partners LLC boosted its stake in shares of Waters by 47.2% in the 4th quarter. Copper Rock Capital Partners LLC now owns 50,367 shares of the medical instruments supplier’s stock valued at $9,812,000 after buying an additional 16,153 shares during the period. Pensionfund Sabic purchased a new position in shares of Waters in the 4th quarter valued at about $1,546,000. Pensionfund DSM Netherlands purchased a new position in shares of Waters in the 4th quarter valued at about $3,091,000. Finally, Parametric Portfolio Associates LLC boosted its stake in shares of Waters by 6.4% in the 3rd quarter. Parametric Portfolio Associates LLC now owns 166,698 shares of the medical instruments supplier’s stock valued at $29,926,000 after buying an additional 10,015 shares during the period. Institutional investors and hedge funds own 92.12% of the company’s stock.

TRADEMARK VIOLATION WARNING: This report was originally published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/01/10/waters-wat-receives-hold-rating-from-barclays.html.

Waters Company Profile

Waters Corporation is an analytical instrument manufacturer. The Company operates through two segments: Waters and TA. It designs, manufactures, sells and services high performance liquid chromatography (HPLC), ultra performance liquid chromatography (UPLC and together with HPLC, referred to as LC) and mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products and post-warranty service plans.

Analyst Recommendations for Waters (NYSE:WAT)

Receive News & Stock Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related stocks with our FREE daily email newsletter.